跳至主要内容
临床试验/NCT06246903
NCT06246903Enrolling By Invitation不适用

INTER-PATHOLOGIST READER STUDY

Orlucent, Inc1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2023年6月15日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
Orlucent, Inc
入组人数
500
试验地点
1
主要终点
Study Success

研究概览

简要总结

This is a post study histology analysis from previously obtained pathology slides.

详细描述

This is a post study histology analysis. Pathologists will use digital histology slide scans of suspicious nevus/nevi obtained from previously conducted studies to provide histopathology gradations of histological features as outlined in the Orlucent histology atlas (LBL0713 Histopathology Atlas for Grading of Dysplastic Nevi and DEF0713-1 Histopathology Definitions for LBL0713).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Histology scans must have been obtained from previous consented subjects that allows post study ad hoc analyses.
  • Histology scans must be available from the data collected from the Orlucent OMS002, SFI001 or SFI003 Studies and are of good quality.

排除标准

  • 未提供

结局指标

主要结局

Study Success

时间窗: 8 months

This is a data collection study. Study success is considered when the interpathology agreement is improved when compared to the agreement identified in Elmore et al. \[5\]. \[(classes/agreement): class I (eg, nevus or mild atypia) / 92% (95% confidence interval 90% to 94); class II (eg, moderate atypia) / 25% (22% to 28%); III (eg, severe atypia or melanoma in situ) / 40% (37% to 44%); IV (eg, pathologic stage T1a (pT1a) early invasive melanoma) / 43% (39% to 46%); and V (eg, ≥pT1b invasive melanoma) / 72% (69% to 75%).\]

次要结局

未报告次要终点

研究者

发起方
Orlucent, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验